The cancer medicine Enhertu will not be included in the basic health insurance package for patients with metastatic stomach cancer because its price is considered too high. Healthcare Minister Sophie Hermans (VVD) wrote to the House of Representatives that negotiations with the manufacturer had not produced sufficient results.

Enhertu is already included in the basic package for women with HER2-positive breast cancer and will remain available to them until 2028.